Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$128.20 USD

128.20
318,467

+0.39 (0.31%)

Updated Aug 7, 2025 12:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (66 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Zacks Equity Research

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (DVA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

DaVita HealthCare (DVA) Down 12.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Top Ranked Growth Stocks to Buy for March 10th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, March 10th

Zacks Equity Research

CVS Health's Latest Alliances to Fortify Kidney-Care Business

by Zacks Equity Research

With a growing incidence of chronic kidney diseases and end-stage renal failure in the United States, CVS Health's (CVS) new partnerships seem to be strategic.

Zacks Equity Research

Time to Focus on DaVita (DVA) for Strong Earnings Growth Potential

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).

Zacks Equity Research

Why DaVita (DVA) Stock Might be a Great Pick

by Zacks Equity Research

DaVita (DVA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Equity Research

DVA or CHE: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

Zacks Equity Research

Has DaVita (DVA) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (DVA) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Top Ranked Growth Stocks to Buy for February 27th

by Zacks Equity Research

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 27th

Zacks Equity Research

Why DaVita (DVA) Could Be an Impressive Growth Stock

by Zacks Equity Research

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider DaVita (DVA).

Zacks Equity Research

Why DaVita (DVA) Could Be Positioned for a Surge

by Zacks Equity Research

DaVita (DVA) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Zacks Equity Research

Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics

by Zacks Equity Research

Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics

Zacks Equity Research

Top Ranked Growth Stocks to Buy for February 19th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 19th

Nilanjan Choudhury headshot

5 Stocks in Focus on Remarkable Relative Price Strength

by Nilanjan Choudhury

Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

Zacks Equity Research

Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson

by Zacks Equity Research

Zacks.com featured highlights include: DaVita, Legg Mason, PG&E, Cardinal Health and McKesson

Zacks Equity Research

Here's Why You Should Add DaVita (DVA) to Your Portfolio Now

by Zacks Equity Research

DaVita (DVA) gains from solid results in the fourth quarter of 2019.

Urmimala Biswas headshot

5 Great GARP Stocks Based on Discounted PEG

by Urmimala Biswas

PEG-based investing can be more rewarding with the addition of a few other relevant parameters.

Zacks Equity Research

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

by Zacks Equity Research

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for February 12th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 12th

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 12th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Zacks Equity Research

Top Ranked Growth Stocks to Buy for February 12th

by Zacks Equity Research

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, February 12th

Zacks Equity Research

DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss

by Zacks Equity Research

DaVita (DVA) gains from dialysis services in the United States in Q4.

Zacks Equity Research

What's in the Cards for DaVita (DVA) This Earnings Season?

by Zacks Equity Research

DaVita (DVA) expects to have gained from calcimimetics in the fourth quarter.